Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Benchmark analyst Bill Sutherland reiterates HeartBeam (NASDAQ:BEAT) with a Speculative Buy and maintains $8 price target.
HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) b...
HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personali...
New Data Presented at Heart Rhythm Society Conference Demonstrates Continued Progress with Company's AI ProgramData Show Th...
Benchmark analyst Bill Sutherland reiterates HeartBeam (NASDAQ:BEAT) with a Speculative Buy and maintains $8 price target.
HeartBeam (NASDAQ:BEAT) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) b...
New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the...
